|
Feb 14
|
Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA)
|
|
Feb 13
|
IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss
|
|
Feb 13
|
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
|
|
Feb 13
|
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC
|
|
Feb 10
|
All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy
|
|
Feb 10
|
IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer
|
|
Dec 30
|
IDEAYA Biosciences Enters Into Licensing Agreement With Jiangsu Hengrui for Cancer Drug Candidate SHR-4849
|
|
Sep 24
|
IDEAYA’s rare cancer drug shows promise as company lays out Phase III plans
|
|
Sep 23
|
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma
|
|
Sep 22
|
IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024
|
|
Aug 26
|
IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
|
|
Aug 1
|
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Jul 31
|
IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen
|
|
Jul 31
|
Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program
|
|
Jul 29
|
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event
|
|
Jul 23
|
How Much Upside is Left in IDEAYA Biosciences (IDYA)? Wall Street Analysts Think 32.97%
|
|
Jun 25
|
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer
|
|
Jun 24
|
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors
|
|
Jun 18
|
Investors in IDEAYA Biosciences (NASDAQ:IDYA) have seen impressive returns of 277% over the past five years
|
|
May 8
|
IDEAYA Biosciences First Quarter 2024 Earnings: US$0.53 loss per share (vs US$0.49 loss in 1Q 2023)
|